



## SOMNOMED 2022 HALF-YEAR FINANCIAL RESULTS INVESTOR CONFERENCE CALL

**SomnoMed Limited (ASX “SOM”, or the Company)** advises its H1 FY22 Financial Results and Investor Presentation will be released to the ASX on 22<sup>nd</sup> February 2022.

Following the release, management will host an investor conference call and webcast including a Q&A session. Participants are encouraged to register before the start of the call using the details below.

**Date:** Tuesday, 22 February 2022

**Time:** 11:00am (Australian Eastern Daylight Time)

**Webcast Link:**

The audio webcast and slide presentation registration will be accessible via the following link:

[https://webcast1.boardroom.media/watch\\_broadcast.php?id=62045d87954d7](https://webcast1.boardroom.media/watch_broadcast.php?id=62045d87954d7)

**Dial In Details:**

Investors wishing to ask questions will be required to register and dial-in via the following link:

[https://vep.express.vc/register/?event\\_id=abae5ea9-1ded-4379-aa00-8fb5062241a5](https://vep.express.vc/register/?event_id=abae5ea9-1ded-4379-aa00-8fb5062241a5)

Once you have registered you will receive an email confirming your attendance with a dial-in number as well as a conference access code and unique PIN number that you must enter to access the call or submit any questions.

14<sup>th</sup> February 2022

**This release has been approved by the Board of SomnoMed Limited**

**For further information please contact**

<b>Corporate</b>	<b>Investors</b>	
Mr. Neil Verdal-Austin	Mr. Craig Sainsbury	Ms. Stephanie Ottens
CEO SomnoMed	Market Eye	Market Eye
+61 406 931 477	+61 428 550 499	+61 434 405 400
Nverdal-austin@somnomed.com	Craig.sainsbury@marketeye.com.au	Stephanie.ottens@marketeye.com.au

**About SomnoMed**

SomnoMed is a public company providing treatment solutions for sleep-related breathing disorders including obstructive sleep apnea, snoring and bruxism. SomnoMed was commercialized on the basis of extensive clinical research. Supporting independent clinical research, continuous innovation and instituting medical manufacturing standards has resulted in SomnoDent<sup>®</sup> becoming the state-of-the-art and clinically proven medical oral appliance therapy for more than 675,000 patients in 28 countries. For additional information, visit SomnoMed at <http://www.somnomed.com.au>